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Activated BRAF mutations affecting the mitogen-activa-
ted protein kinases (MAPK) pathway are present in 50% 
of metastatic melanomas. Targeted therapies have been 
developed to block such mutations (1, 2). There is a risk 
of other components of the MAPK signalling pathway, 
such as MEK, being reactivated after the use of BRAF 
inhibitors (3–5). Given the evidence of drug resistance 
and side-effects of BRAF inhibitors, combined treat-
ments with BRAF and MEK inhibitors are being tested 
in clinical trials for metastatic melanoma. Trametinib 
is one of these MEK inhibitors. Skin toxicities from 
BRAF inhibitors, such as photosensitivity, palmoplantar 
keratoderma (PPK) and keratosis pilaris (KP), have been 
reported (4, 6–11). Also, non-melanoma skin cancers 
(NMSC) are considered one of the most significant side-
effects (3, 11). We report here the profile of skin toxicities 
from vemurafenib, dabrafenib alone, or dabrafenib and 
trametinib combined treatment. 
MATERIALS AND METHODS
A total of 59 patients (47 treated with only vemurafenib (71%) or 
dabrafenib (9%) and 12 with dabrafenib and trametinib in combi-
nation (20%)) were seen in the Hospital Clinic, Barcelona, Spain. 
All patients underwent dermatological evaluation at baseline and 
monthly during treatment, or whenever patients presented with a 
complaint. All skin toxicities, including squamous-proliferative, 
keratinizing, inflammatory, follicular/adnexal disorders, were 
evaluated clinically and/or histopatho logically. Any patients 
presenting new melanocytic tumours or changes in their pre-
existing naevi were excluded from the current study. The study 
was approved by the ethics committee and patients gave their 
written informed consent. 
Statistical analysis with significant value (p ≤ 0.05) was perfor-
med with paired-sample Student t-test for differences between 
the duration of toxicities and Pearson χ2 with 95% confidence 
interval (95% CI) for analysing the significance of the existence 
of each side-effect. 
RESULTS
Demographics and all skin toxicities reported in our 
series are listed in Table SI1. Only 2 patients (3.4%) had 
a previous history of actinic keratosis (AK). Twenty 
patients (33.8%) had seborrhoeic keratoses (SK) at 
baseline. At least one skin toxicity was diagnosed in 53 
(89.8%) patients. Risk of presenting skin toxicities was 
not related to sex, age, duration, or type of treatment. 
Fourteen patients (23.7%) developed more than one 
NMSC during treatment. The patients with kerato-
acanthoma (KA) and squamous cell carcinoma (SCC) 
were significantly older than those without KA and 
SCC (p = 0.03 and p = 0.02, respectively). A total of 32 
KAs were detected in 12 patients (mean 2.7 per pa-
tient). Patients with SCC had a higher number of KAs 
(p = 0.002). NMSC diagnosis was related to neither 
sun-exposed areas nor history of NMSC. Development 
of NMSC-including or not including AK, and KA was 
higher in patients with only single treatment (odds ratio 
[OR]-combined: 0.5 p = 0.02, OR: 0.74 p = 0.05 and 
OR-combined: 0.75 p = 0.05). All patients with SCC 
were treated with only one drug (OR: 0.9 p = 0.29). The 
proportion of patients who developed NMSC, KA and/or 
AKs was lower in combined therapy (OR: 0.5, p = 0.02, 
OR: 0.74, p = 0.05 and OR: 0.66, p = 0.01). 
PPK was associated with longer duration of treat-
ments (p = 0.003), but there was no difference between 
combined compared with single drug treatments (OR: 
1.021, p = 0.99). When comparing dabrafenib single 
drug against vemurafenib or combined treatments, the 
number of patients with PPK on dabrafenib single agent 
was higher than the other 2 (OR: 3, p = 0.01 and OR: 3.8, 
p = 0.001). The patients presenting with SK were older 
than the others (p = 0.003). NMSC and AK were detec-
ted earlier and with higher number of KAs in patients 
with SK than those without ((p = 0.006, p = 0.02) and 
(p =  0.03)). The number of SKs was higher in patients 
with only dabrafenib treatment (p = 0.01). Of patients 
with verrucous papillomas, 92.8% received single-drug 
therapy. 
KP appeared in younger patients (p = 0.02) and was 
not prevented by combined regimen (OR: 0.96, p = 1.00). 
The number of SKs was lower in patients with KP 
(p = 0.05). Acneiform eruption/folliculitis (AE-F) was 
more frequent in males (OR: 5.6, p = 0.02 and OR: 1.37, 
p = 0.01) and related to longer duration of treatments 
(p = 0.002). Most of the patients presenting hair loss 
received combined therapy (OR: 1.6, p = 0.48) (Fig. 
S11). Photosensitivity was present in both single-drug 
treatments without any differences (OR: 1.12, p = 0.90), 
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and was not prevented by combined therapy (OR: 1.35, 
p = 0.71). Skin rash presented earlier in patients under 
combined treatment, the same as in patients treated with 
dabrafenib alone (p = 0.01 and p = 0.01). Out of 5 patients 
presenting vitiligo, 3 of these (5.1%) were receiving 
treatment with only dabrafenib (Fig. S11).
DISCUSSION
Our experience supports the view that skin toxicities 
are highly frequent during MAPK-target therapies, even 
under combined regimen with BRAF and MEK inhibi-
tors. Similar to previous reports, single-drug treatment 
demonstrated a higher frequency and earlier appearance 
of NMSC-including or not including AK, than combined 
treatment (7–11). Indeed all SCCs were presented under 
this regime. Most importantly, patients presenting SCC 
and KA were older and there was no relationship between 
skin types or previous history of NMSCs. Our study de-
monstrated an association between the diagnosis of new 
SKs and early development of NMSC and an increased 
number of KAs. In accordance with previous reports 
our study shows that the number of SKs was higher in 
patients receiving dabrafenib treatment (12). Based on 
our findings and those of Hafner et al. (13), who sug-
gested that SK could be the result of MAPK pathway 
mutations, patients with SK may develop NMSC sooner, 
and the number of KAs could be higher in these patients.
Our study supports the fact that photosensitivity occurs 
during the early stages of BRAF inhibitor treat ments 
and, notably, demonstrates that combination with MEK 
inhibitors does not prevent photosensitivity. Despite the 
small sample size with dabrafenib in our series, which 
is a limitation of our study, there appears to be no diffe-
rence in photosensitivity between the 2 selective BRAF 
inhibitors (8–11). 
Several studies have described skin-rash as KP, folli-
culocentric and maculopapular (5, 8, 9, 14). We observed 
the maculopapular rash less frequently than other studies 
and at earlier onset in combination and dabrafenib-only 
treatments. In addition, KP was seen in younger patients 
and showed a negative relationship between the deve-
lopment of KP and the number of SKs.
In contrast to previous reports, PPK was diagnosed 
more frequently in patients on the dabrafenib regimen 
(8, 10, 12). Furthermore, the duration of treatment was 
longer in these patients. Importantly, our study found 
that combined therapy did not prevent PPK. Acneiform 
eruption/folliculitis was more frequent in our series and 
significantly seen in males (8, 10–12). Interestingly, 
gender was not related to any other specific toxicity. We 
hypothesized that this could be the result of longer dura-
tion of therapy follow-up in our series. In our experience 
vitiligo was more frequent with dabrafenib therapy, 
compared with 2 cases reported in the literature during 
vemurafenib treatment (15). Interestingly, for the first 
time, to our knowledge erythema of the conjunctiva has 
been seen as a toxicity developed during early stage of 
therapy. 
In conclusion, combined treatment of MAPK inhibi-
tors may prevent some of the skin toxicities, as expected. 
However, the most frequent side-effects, such as KP, PPK 
and photosensitivity, cannot be prevented. 
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